Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil

Clinical Microbiology and Infection

Volumn 14, Issue 2, 2008, Pages 116-123

  Kuti, J L ^a   Kiffer, Carlos R V ^b   Mendes, C M F ^b   Nicolau, D P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Fleury   (Brazil)

Author keywords

Linezolid; Monte Carlo simulation; Pharmacodynamic targets; Staphylococci; Teicoplanin; Vancomycin

Indexed keywords

LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; BRAZIL; CLINICAL TRIAL; COAGULASE POSITIVE STAPHYLOCOCCUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 38049055375     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01885.x     Document Type: Article

References (26)

1. Kuti JL, Nicolau DP. Making the most of surveillance studies: Summary of the OPTAMA Programme. Diagn Microbiol Infect Dis 2005; 53: 281-287.
2. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
3. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of anti-infectives with pharmacodynamics and Monte-Carlo simulation. Pediatr Infect Dis J 2003; 22: 982-992.
4. Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003; 47: 292-296.
5. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 2004; 48: 2464-2470.
6. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-2402.
7. Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate therapy. Crit Care Med 2006; 34: 700-706.
8. Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-955.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement, M100-S16. Wayne, PA: CLSI, 2006.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disc susceptibility tests, approved standard, 9th edn, M2-A9. Wayne, PA: CLSI, 2006.
11. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003; 47: 548-553.
12. Lortholary O, Tod M, Rizzo N et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996; 40: 1242-1247.
13. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1998; 32: 848-852.
14. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-942.
15. Andes D, van Ogtrop ML, Peng J, Craig WA. Invivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46: 3484-3489.
16. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000; 57: 84-89.
17. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 (suppl): 35-39.
18. Drusano GL, Preston SL, Hardalo C et al. Use of preclinical data for selection of a phaseII/III dose for evernimicin and identification of a preclinical breakpoint. Antimicrob Agents Chemother 2001; 45: 13-22.
19. Wilson APR. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000; 39: 167-183.
20. Harding I, MacGowan AP, White LO, Darley ESR, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: Relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000; 45: 835-841.
21. Fortun J, Navas E, Martinez-Beltran J et al. Short-course therapy for right sided endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001; 33: 120-125.
22. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44: 1536-1542.
23. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-1423.
24. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-1797.
25. Knudson JD, Fuursted K, Espersen F, Frimodt-Moller N. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci invitro and invivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother 1997; 41: 1910-1915.
26. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44: 1247-1254.